Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR

Gilbert, Jill; Le Tourneau, Christophe; Mehanna, Hisham; Fayette, Jerome; Goswami, Trishna; Emeribe, Ugochi; Jarkowski, Anthony; Melillo, Giovanni; Siu, Lilian L

doi:10.1186/2051-1426-3-S2-P152

Article metrics
Last updated: Thu, 25 Apr 2024 16:47:41 Z

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR

Access & Citations

1224

Article Accesses
0

Web of Science
5

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.